Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

Abstract

Homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high remission rate and provide a survival advantage in acute myeloid leukemia (AML). To investigate whether HAA is an ideal induction regimen for t(8;21)AML, we retrospectively analyzed the data of 140 patients from the last 8 years in our center. When achieving complete remission (CR), the post-remission treatment was administered as a minimal residual disease-directed risk-stratification treatment protocol. The RUNX1/RUNX1T1 transcript level was assessed by RT-qPCR. The last follow-up was conducted in October 2015. In total, thirty patients received an HAA regimen as the induction treatment. The CR rate after one cycle of the HAA regimen was 93.3% (28/30). One patient achieved partial remission, and one had no response. No patients died during induction treatment. The median fold decrease of the RUNX1/RUNX1T1 transcript level was 200 (1-358000), and 16.7% (5/30) patients achieved >3 log decrease after one cycle of the HAA regimen. The estimated 4-year disease-free survival and overall survival were 89.9% and 90.8%, respectively. We concluded that the HAA regimen is highly effective as the first course of induction therapy for t(8;21) AML, and this needs to be confirmed in a large population in the future.

• Authors: Hong-Hu Zhu, Hao Jiang, Qian Jiang, Jin-Song Jia, Ya-Zhen Qin, Xiao-Jun Huang
• Journal: Leukemia research (Leuk Res) Vol. 44 Pg. 40-4 (May 2016) ISSN: 1873-5835 [Electronic] England
• PMID: 26994850 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2016 Elsevier Ltd. All rights reserved.

Chemical References

• AML1-ETO fusion protein, human
• Core Binding Factor Alpha 2 Subunit
• Harringtonines
• Oncogene Proteins, Fusion
• RNA, Messenger
• RUNX1 Translocation Partner 1 Protein
• Cytarabine
• Homoharringtonine
• Aclarubicin

Topics

• Aclarubicin (administration & dosage)
• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chromosomes, Human, Pair 21 (genetics)
• Chromosomes, Human, Pair 8 (genetics)
• Core Binding Factor Alpha 2 Subunit (genetics)
• Cytarabine (administration & dosage)
• Female
• Follow-Up Studies
• Harringtonines (administration & dosage)
• Homoharringtonine
• Humans
• Leukemia, Myeloid, Acute (drug therapy, genetics, mortality, pathology)
• Male
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Staging
• Oncogene Proteins, Fusion (genetics)
• Prognosis
• RNA, Messenger (genetics)
• RUNX1 Translocation Partner 1 Protein
• Real-Time Polymerase Chain Reaction
• Remission Induction
• Retrospective Studies
• Reverse Transcriptase Polymerase Chain Reaction
• Survival Rate
• Translocation, Genetic (genetics)
• Young Adult